<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596059</url>
  </required_header>
  <id_info>
    <org_study_id>CEI00320171130/07/052020</org_study_id>
    <nct_id>NCT04596059</nct_id>
  </id_info>
  <brief_title>The Journey of Children With Cow's Milk Protein Allergy in Mexico.</brief_title>
  <acronym>Friso02</acronym>
  <official_title>A Retrospective and Comparative Study on the Journey of Children With Cow´s Milk Protein Allergy in Mexico: Current Practice in Allergy Management in Mexican Children Aged ≤24 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FrieslandCampina</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sprim Advanced Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FrieslandCampina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To gain insights on the application, use and effectiveness of Frisolac Gold Intensive HA and&#xD;
      Frisolac Gold PEP AC with reference to improvement of CMPA symptoms and to determine the&#xD;
      methodology used by Mexican Health Care Professionals (HCPs) in the clinical practice (i.e.&#xD;
      diagnosis and dietary management) of CMPA in Mexican children (≤24 months) diagnosed with or&#xD;
      suspected of CMPA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Growth</measure>
    <time_frame>Can be 2 weeks up to 2 months</time_frame>
    <description>the proportion of subjects with weight gain compared to the previous visit (%)&#xD;
the proportion of subjects with height gain compared to the previous visit (%)&#xD;
the proportion of subjects with both weight and height gain compared to the previous visit (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dermatological symptoms (SCORAD score)</measure>
    <time_frame>Can be 2 weeks up to 2 months</time_frame>
    <description>The proportion of subjects with an 1-point improvement in their SCORAD intensity category in between 2 visits (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of symptoms</measure>
    <time_frame>Can be 2 weeks up to 2 months</time_frame>
    <description>Type of symptoms (e.g. crying, regurgitation, stool consistency, respiratory, enteropathies and colitis) (based on clinical diagnosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptoms</measure>
    <time_frame>Can be 2 weeks up to 2 months</time_frame>
    <description>Number of symptoms (e.g. crying, regurgitation, stool consistency, respiratory, enteropathies and colitis) (based on clinical diagnosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of symptoms</measure>
    <time_frame>Can be 2 weeks up to 2 months</time_frame>
    <description>Severity of symptoms on first and second visit (based on clinical diagnosis)</description>
  </secondary_outcome>
  <enrollment type="Actual">79</enrollment>
  <condition>Cow's Milk Protein Allergy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Frisolac Gold Intensive HA</intervention_name>
    <description>Regular medical care</description>
    <other_name>Frisolac Gold PEP AC</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Mexican children (≤24 months) diagnosed with or suspected of CMPA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with electronic/physical medical records that contain sufficient data to&#xD;
             answer the primary question (i.e. data on growth and dermatological symptoms (based on&#xD;
             the SCORAD score) at diagnosis and follow up data of at least 2 months or successful&#xD;
             completion of therapy according to the PI (whichever comes first).&#xD;
&#xD;
          -  Subjects ≤24 months of age at the moment of suspected or diagnosed CMPA with records&#xD;
             available between January 2016 to September 2020.&#xD;
&#xD;
          -  Subjects prescribed with Frisolac Gold Intensive HA and/or Frisolac Gold PEP AC for&#xD;
             the dietary management of their CMPA symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects using other formula products/breast milk alongside Frisolac Gold Intensive HA&#xD;
             or Frisolac Gold PEP AC during the time of their participation in the study.&#xD;
&#xD;
          -  Premature children, or children with low birth-weight (weight at birth &lt;2.5 kg).&#xD;
&#xD;
          -  Subjects diagnosed with a metabolic condition that impacts development and growth.&#xD;
&#xD;
          -  Subjects diagnosed with a congenital condition and/or with prior or current disease&#xD;
             that in the opinion of the PI could potentially interfere with their participation in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa E Huerta Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica de Alergia Pediátrica, México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Zepeda Ortega, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica San Antonio, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marlene Ruiz Castillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Niño DIF Hildago, Mexico; Consultorio de Pediatría Pachuca, Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica San Antonio</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica de Alergia Pediátrica</name>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio de Pediatria</name>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Niño DIF</name>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

